Mesabi Trust (MSB NYSE) stock market data APIs
$23.285
-0.23(-1%)
as of August 7, 2026
Try our APIs with
free plan!
Mesabi Trust Financial Data Overview
Price chart is built with
Anychart
Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was incorporated in 1961 and is based in New York, New York.
Prev. Close
23.285
Open
23.0573
High
23.3257
Low
22.965
52 wk Range
21.5521-41.5816
Market Cap
302 M
P/E Ratio
26.7674
Shares Outstanding
13 120 K
Revenue
15 035 K
EPS
0.0829
Dividends (Yield)
0.0417
Beta
0.327
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mesabi Trust (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mesabi Trust data using free add-ons & libraries
Get Mesabi Trust Fundamental Data
Mesabi Trust Fundamental data includes:
- Net Revenue: 15 035 K
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mesabi Trust News
New
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pai...
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for C...
Mesabi Trust Press Release
NEW YORK, July 14, 2026--(BUSINESS WIRE)--Announcement of Mesabi Trust Distribution The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Inter...
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast Limited Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic ...
Get Mesabi Trust fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
